Genomma Lab Internacional SAB de CV
Genomma Lab Internacional has a debt-to-equity ratio of 0.69, indicating a moderate level of leverage, and a current ratio of 1.77, suggesting it has sufficient short-term assets to cover its short-term liabilities. The company's liquidity position is assessed as medium, with free cash flow of 630.14 million MXN and operating cash flow of 2.05 billion MXN, but its net cash position is negative after subtracting total debt. The company's profitability is reflected in a return on equity of 14.47% and a return on assets of 6.74%, which are key metrics for evaluating performance in the pharmaceutical industry. These figures suggest that Genomma Lab Internacional is generating a reasonable return on its equity and assets, though the exact comparison to industry medians is not provided in the available data. Geographically, the company's revenue is primarily concentrated in Mexico, as disclosed in its segments, with no significant international revenue streams reported in the available data. This concentration may expose the company to regional economic and regulatory risks. Looking ahead, the company is expected to maintain a stable growth trajectory, with no specific numeric deltas provided for the current or next fiscal year. However, the company's operating income of 3.76 billion MXN and net income of 1.61 billion MXN indicate a solid earnings base. The risk assessment for Genomma Lab Internacional highlights a medium liquidity risk and a low dilution risk. The company's capital structure includes long-term debt of 7.63 billion MXN and cash and equivalents of 2.86 billion MXN, which may affect its financial flexibility. No dilution sources are identified in the available data, and the dilution potential is assessed as low. Recent events and filings do not provide specific details on new product launches, regulatory changes, or strategic partnerships. Analysts have provided a mean price target of 28.10 MXN and a median price target of 29.00 MXN, with a mean recommendation of 2.29, indicating a generally positive outlook.
Business. Genomma Lab Internacional SAB de CV is a pharmaceutical company that develops, produces, and distributes a range of pharmaceutical products, primarily in the Mexican market.
Classification. Genomma Lab Internacional is classified under the Healthcare economic sector, specifically in the Pharmaceuticals & Medical Research business sector, with a high confidence level of 0.92.
- Genomma Lab Internacional has a moderate level of leverage with a debt-to-equity ratio of 0.69.
- The company's return on equity of 14.47% indicates strong profitability relative to its equity base.
- The company's liquidity position is assessed as medium, with free cash flow of 630.14 million MXN.
- The company's revenue is primarily concentrated in Mexico, which may expose it to regional economic and regulatory risks.
- Analysts have provided a generally positive outlook, with a mean price target of 28.10 MXN and a median price target of 29.00 MXN.
- --
- # RATIONALES
- ```json
- Net cash is negative after subtracting total debt.